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Abstract
Background: Damage-associated molecular patterns (DAMPs) are associated with immunogenic cell death and
have the ability to enhance maturation and antigen presentation of dendritic cells (DCs). Specific microtubule-
depolymerizing agents (MDAs) such as colchicine have been shown to confer anti-cancer activity and also trigger
activation of DCs.
Methods: In this study, we evaluated the ability of three MDAs (colchicine and two 2-phenyl-4-quinolone
analogues) to induce immunogenic cell death in test tumor cells, activate DCs, and augment T-cell proliferation
activity. These MDAs were further evaluated for use as an adjuvant in a tumor cell lysate-pulsed DC vaccine.
Results: The three test phytochemicals considerably increased the expression of DAMPs including HSP70, HSP90
and HMGB1, but had no effect on expression of calreticulin (CRT). DC vaccines pulsed with MDA-treated tumor cell
lysates had a significant effect on tumor growth, showed cytotoxic T-lymphocyte activity against tumors, and
increased the survival rate of test mice. In vivo antibody depletion experiments suggested that CD8
+ and NK cells,
but not CD4
+ cells, were the main effector cells responsible for the observed anti-tumor activity. In addition,
culture of DCs with GM-CSF and IL-4 during the pulsing and stimulation period significantly increased the
production of IL-12 and decreased production of IL-10. MDAs also induced phenotypic maturation of DCs and
augmented CD4
+ and CD8
+ T-cell proliferation when co-cultured with DCs.
Conclusions: Specific MDAs including the clinical drug, colchicine, can induce immunogenic cell death in tumor
cells, and DCs pulsed with MDA-treated tumor cell lysates (TCLs) can generate potent anti-tumor immunity in
mice. This approach may warrant future clinical evaluation as a cancer vaccine.
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Background
Cancer vaccines seek to treat malignancies by
approaches that induce presentation of tumor-associated
antigens (TAAs) in contexts that elicit potent CD4
+ and
CD8
+ T-cell responses and break the tolerance of the
host immune system to tumor growth [1,2]. Immunity,
including innate immunity and antigen-specific adaptive
immunity, and tolerance toward tumors is orchestrated
by a network of antigen-presenting cells, the most
crucial of which are dendritic cells (DCs) [3,4]. Although
clinical trials based on DC-based vaccines have been
initiated for certain malignancies [5], unlike in pathogen
infection, activation of DCs in tumor microenviron-
ments is weak and ineffective [1,6]; therefore, the devel-
opment of DC-based vaccines that can not only induce
powerful activation of DCs, but also enhance tumor-
specific immunity by breaking tolerance is a challenge.
Most anticancer chemotherapeutics influence both
tumor cells and the associated immune systems [7].
However, the mechanisms that underlie the various
cellular activities that induce immune response, and
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genic or tolerogenic, are still unclear [8,9]. A key-lock
paradigm has been proposed to explain the relationship
between immunogenic cell death and DCs [9]. Immuno-
genic cell death is characterized by expression of calreti-
culin (CRT) and then heat shock proteins (HSPs),
HSP70 and HSP90 on the cell surface, and the release
of high-mobility group box 1 (HMGB1) proteins. CRT,
HSPs and HMGB1 can function as immunological adju-
vants for phagocytosis, cross presentation of tumor-
derived antigens and antigen processing and presenta-
tion by DCs [10]. It is, therefore of interest to investi-
gate the molecular and cellular behaviors of these
immunogenic cell death-associated proteins in tumor
cell lysates (TCLs) with an eye toward improving the
efficacy of TCL-pulsed DC-based vaccines.
A cornucopia of chemotherapeutic drugs including
microtubule-targeted agents can induce cell death [11].
These can be classified mainly into two groups [12]:
microtubule-depolymerizing agents (MDAs), including
vinca alkaloids and colchicine, which inhibit tubulin
polymerization; and microtubule-polymerizing agents
such as paclitaxel, which stimulate tubulin polymeriza-
tion. Recent studies indicate that functional microtu-
bules are required for antigen processing by DCs [13]
and microtubules mediate NF-B activation in the TNF-
a signaling pathway [14]. Furthermore, in terms of acti-
vation of DCs, colchicine was found not only to trigger
the maturation of DCs in vitro and in vivo [15], but also
promote antigen-cross presentation by murine DCs [16].
On the other hand, with respect to enhancement of
antitumor effect, vincristine increased the antitumor
effect of DC-based immunotherapy [17], and was also
suggested to enhance the immunogenicity of chronic
lymphocytic leukemia cells [18]. Taken together, these
f i n d i n g ss u g g e s tt h a tM D A sm a yb ea b l et oe n h a n c e
tumor-specific immune response generated by activation
of DCs and induce immunogenic cell death. Both, there-
fore, could conceivably be used in cancer immunother-
apy approaches.
Numerous dendritic cell-based strategies have been
employed for developing anti-cancer vaccines, including
defined peptide-loaded DCs [19,20], genetically-modified
DCs [21,22], DC-derived exosomes [5], apoptotic cell-
loaded DCs [23], and tumor cell lysate (TCL)-pulsed
DCs [19,24,25]. The possible advantage of the use of
whole cell lysates as the source for vaccination is that a
full complement of TAAs, including both MHC class I
and class II-restricted tumor associated epitopes may be
provided, thus reducing the possibility of immune
escape by antigen loss variants [26]. A common techni-
que used to generate TCLs is removal of the solid cellu-
lar debris by centrifugation after repeated cycles of
freezing and thawing of target tumor cells [19,26,27].
The protective effect of DCs pulsed with TCLs has been
proven in animal models [24,27], and reported in a
range of clinical trials [19,25,28]. Nonetheless, the mod-
est activities reported for TCL-pulsed DC-based vac-
cines so far need to be further improved and optimized,
either in the presence or absence of DC-maturation sti-
muli [25,28].
In this study, we evaluated the effect of colchicine and
two 2-pheny-4-quinolone analogues, which, as MDAs,
were shown to confer antitumor effects via inhibition of
tubulin polymerization [29-31] on the activation of DCs
and subsequent T-cell proliferation. We also investi-
gated the effect of these MDAs on mediating immuno-
genic cell death in treated B16 melanoma cells via
induction of DAMP stress proteins. Possible use of the
test MDAs as adjuvants for use in TCL-pulsed DC vac-
cines was also evaluated. Our findings showed that 2-
pheny-4-quinolone analogues could induce phenotypic
maturation of DCs. These MDAs were able to augment
CD4
+ and CD8
+ T cell proliferation. TCLs generated
from MDA treatment were further able to improve the
efficacy of TCL-pulsed DC vaccines. Our findings thus
provide useful information for potential clinical applica-
tion of MDAs in chemotherapy or cancer
immunotherapy.
Methods
Chemicals and reagents
2-(3-chlorophenyl)-6,7-methylenedioxyquinolin-4-one
(CMQ) and 2-(3-fluorophenyl)-6,7-methylenedioxyqui-
nolin-4-one (FMQ) were synthesized as previously
described [32]. Each compound was dissolved in
dimethyl sulfoxide (DMSO) to obtain a stock solution,
and a final concentration of 0.1% DMSO was used in
the cell assays. RPMI 1640 medium, DMEM, fetal
bovine serum (FBS), penicillin, streptomycin, and all
other tissue culture reagents were obtained from
GIBCO/BRL Life Technologies (Grand Island, NY)
unless otherwise indicated. Colchicine, DMSO, and thia-
zolyl blue tetrazolium bromide (MTT), and other che-
mical agents were purchased from Sigma (St Louis,
M O ) .T h ea n t i b o d yt ob-actin and HRP-labeled anti-
mouse and anti-rabbit IgGs were obtained from Santa
Cruz Biotechnology Inc. (Santa Cruz, CA). Antibodies
to HSP70, calreticulin, HMGB1 and survivin were pur-
chased from Cell Signaling Technologies (Boston, MA).
The antibody to glypican-3 was purchased from Abcam
(Cambridgeshire, UK), and the antibody to HSP90 was
purchased from Millipore (Billerica, MA),
Mice
Male C57BL/6JNarl mice (6-8-weeks old) were pur-
chased from the National Laboratory Animal Breeding
and Research Center, Taipei, Taiwan. All mice were
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at 24 ± 2°C and 40-70% humidity with a 12 h light/dark
cycle under specific pathogen-free conditions. All facil-
ities were approved by the Academia Sinica Institutional
Animal Care and Utilization Committee, and all animal
experiments were conducted according to institutional
guidelines.
Cell lines
The mouse B16F10 (B16) melanoma cells were obtained
from American Type Culture Collection (ATCC; Mana-
ssas, VA, USA). Cell cultures were maintained in Dul-
becco’s modified Eagle’s medium (DMEM) with 1.5 g/l
sodium bicarbonate, 10% fetal bovine serum (FBS), 100
mg/ml streptomycin and penicillin, and 2 mM L-gluta-
mine. Mouse bone marrow cells and bone marrow-
derived dendritic cells (BMDCs) were cultured in RPMI
1640 containing 10% FBS, 50 mM 2-mercaptoethanol,
100 mg/ml streptomycin and penicillin, and 2 mM L-
glutamine.
Cell viability determined by MTT assays
B16F10 cells (1 × 10
4/well) were grown in 96-well plates
in DMEM supplemented with 10% FBS in a 5% CO2
incubator at 37°C. After incubation for 16 hours, culture
media were removed and treated with 9 specified con-
centrations of CMQ-1 (0.001-10 mM) for 24, 48 and 72
hours. Test culture medium was then replaced with 100
μl culture medium containing 3-(4,5-dimethylthiozole-2-
yl)-2,5-biphenyl tetrazolium bromide (MTT) at a con-
centration of 0.5 mg/ml per well for 4 hours, and then
light absorbance was measured with a spectrophot-
ometer at 570 nm. Cell viability was expressed as per-
centage of vehicle control cells (containing DMSO 0.1%
as 100%) cultured in the absence of any test compounds.
Preparation of tumor cell lysates (TCLs)
B16 cell lysates were prepared as described previously
with slight modification [33]. Cells (5 × 10
6)w e r e
seeded onto a 15-cm dish maintained for 16 hours, and
then treated with DMSO (0.1%), doxorubicin (2.5 μM),
colchicine (2.5 μM), CMQ (2.5 μM) or FMQ (2.5 μM)
for 24 hours. After scraping, centrifuging and rinsing
twice with PBS, cells were suspended at a concentration
of 1 × 10
7 cell/ml in PBS, frozen in liquid nitrogen for 2
minutes. Cells were then thawed in a 37°C water bath
for 4 minutes and sonicated for 4 minutes to further
disrupt the cell suspension. The freeze-thaw-sonicated
cycle was repeated for four times in rapid succession.
The suspension was then centrifuged at 17,000 × g for
15 minutes and the supernatant (tumor cell lysate) was
stored at -80°C.
Western blot analysis
Tumor cell lysate samples were prepared as previously
described. In order to determine the expression levels
of DAMPs and tumor-associated antigens, B16 tumor
cells were harvested after treatment with indicated test
compounds, followed by four freeze-thaw cycles. Sam-
ples were subsequently resolved by SDS-PAGE using
8%, 10% or 15% gels. The resolved proteins were trans-
ferred to a PVDF Immobilon-P membrane (Millipore,
Bedford, CA.), and the membrane was blocked with
5% non-fat dry milk in PBST buffer [phosphate-buf-
fered saline (PBS) containing 0.1% Tween 20] for 60
minutes at room temperature. The membranes were
then incubated overnight at 4°C with commercially
available antibodies (1:1000 dilutions). Loading of
equal amounts of protein was assessed using mouse b-
actin. The blots were rinsed three times with PBST
buffer for 5 minutes. Washed blots were incubated
with HRP-conjugated secondary antibody (1:10,000
dilution) and then washed again three times with
PBST buffer. The transferred proteins were visualized
with an enhanced chemiluminescence (ECL) detection
kit (Amersham Pharmacia Biotech, Buckinghamshire,
UK). Quantification of bands was performed using
Image J software.
Generation of mouse bone marrow-derived dendritic cells
(BMDCs)
BMDCs were generated as previously described with
slight modification [34]. Briefly, on Day 0, the bone
marrow was collected from femurs and tibiae after
euthanasia and then flushed with RPMI-1640 medium
using a syringe with a 0.45-mm needle. Red blood cells
in suspension were lysed with ACK lysing buffer (150
mM NH4Cl, 1.0 mM KHCO3, 0.1 mM EDTA) for 5
min. Bone marrow cells were suspended at a density of
1×1 0
7cells/30 ml in RPMI-1640 containing 10% FBS, 2
mM L-glutamine, 1% of nonessential amino acids and
100 U/mL penicillin and 100 μg/mL streptomycin) sup-
plemented with 20 ng/mL of GM-CSF (Peprotech,
Rocky Hill, NJ) in 15-cm dishes at 37°C with 5% CO2.
On day 2, two-thirds of the medium was removed and
30 mL fresh medium with GM-CSF was added to the
cells. On day 5, culture plates were gently swirled and
the floating and loosely adherent cells were discarded.
Aliquots of 75% culture media were replenished with 20
ng/mL GM-CSF (PeproTech EC, London, UK) and 20
ng/mL IL-4 (Peprotech, Rocky Hill, NJ). On day 7, non-
adherent cells were collected and used as the immature
DC population for subsequent tests and analyses. More
than 92% cells were CD11c
+ as measured by flow
cytometry.
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DCs were suspended in RPMI-1640 medium at a con-
c e n t r a t i o no f2×1 0
6 cells/3 ml in 6-well plate. Tumor
cell lsysates (TCLs, 400 μg) from the various treatments
described in “Preparation of tumor cell lysates (TCLs)”
a b o v ew e r ea d d e dt ot h eD Cc u l t u r ef o r1 2h o u r sa n d
then 1 μg/ml of lipopolysaccharides (LPS) was added as
a maturation stimulus. After incubation with LPS for 12
hours, TCLs-pulsed DCs were harvested as DC vaccines
for immunization.
Different culture conditions for tumor cell
lysate-pulsed DCs
DCs generated from bone marrow were incubated under
culture conditions with a regimen of pulsing and stimu-
lating period: (i) without GM-CSF (20 ng/ml) and IL-4
(20 ng/ml), (ii) GM-CSF (20 ng/ml), (iii) GM-CSF (20
ng/ml) and IL-4 (20 ng/ml). These DCs were then
further treated with: vehicle only without any treatment
(imDCs), LPS for 24 hours (maDCs), TCL plus LPS for
24 hours (CTCL-CMQ) or TCL for 12 hours and then
LPS for 24 hours (TCL-CMQ).
Measurement of expression of IL-12p70 and IL-10
Expression of IL-12p70 and IL-10 were measured using
a commercial ELISA kit (R&D Systems, Minneapolis,
MN) according to the manufacturer’si n s t r u c t i o n s .
Briefly, flat-bottomed 96-well plates were coated with
capture antibodies, incubated with samples for 2 hours,
washed four times with PBS, developed with appropriate
biotinylated secondary antibodies for 2 hours and
washed a further four times with PBS. Then plates were
incubated with streptavidin-HRP conjugates for 30 min-
utes, washed five times, TMB substrate solution was
then added and stopped by 0.2 M sulfuric acid. The OD
values were measured at 450 nm.
In vivo B16 melanoma tumor model
For the tumor challenge, B16 tumor cells were collected at
80% confluence, washed, resuspended in PBS, and injected
subcutaneously (10
5 cells/50 μl/mouse) into the right
flanks of mice. On day 8 post-tumor cell inoculation
(when the tumor volume reached 50-80 mm
3), test mice
were vaccinated with different preparations of TCL-pulsed
DCs (5 × 10
5 cells/50 μl/mouse) by intratumoral injection.
C57BL/6 mice were divided into seven experimental
groups (eight mice per group). The seven treatments were:
(i) PBS (control, Ctrl), (ii) mature DCs (maDC), (iii) TCL-
D M S O ,( i v )T C L - D X ,( v )T C L - C ,( v i )T C L - C M Q ,( v i i )
TCL-FMQ. These vaccination sets were used for priming
and booster vaccination of mice. Two boosters were per-
formed, one on day 10 and one on day 13. Ten days after
the second booster (on day 23), splenocytes were har-
vested from immunized mice and assayed for cytotoxic T
lymphocyte (CTL) activity. Tumor volumes were deter-
mined from the length (L) and width (W) of test tumors,
as measured with a caliper in a blinded manner, by the
formula: V = L × W
2/2. Survival of mice was recorded
over 40 days following tumor challenge.
Tumor cell lysis by cytotoxic T lymphocyte (CTL)
Cytotoxicity assays for specific cell lysis were performed
using the DELFIA EuTDA cytotoxicity method [35]. B16
cells were trypsinized and suspended at a of density of 1 ×
10
6 cells/ml, then 5 μl BATDA labeling agent was added
to each 4 ml of cells for 15 minutes at 37°C. After labeling,
cells were centrifuged, washed in PBS, and resuspended at
ad e n s i t yo f5×1 0
4 cells/ml in DMEM. Next, 5 × 10
3
BATDA-labeled B16 target cells in 100 μl of medium were
plated into each well of 96-well V-bottomed plates. Sple-
nocytes (effector cells) from vaccinated animals 7 days
after second boosting were added to the target cells with
ratios ranging from 1:5 to 1:80 for 3 hours at 37°C. Condi-
tions were also established to measure the background
level, spontaneous release and maximal lysis. After incuba-
tion and centrifugation, 20 μl of supernatant containing
released BATDA was transferred to 200 μlo fe u r o p i u m
solution in a 96-well flat-bottomed plate which was shaken
for 15 minutes at 25°C. Plates were analyzed on a time-
resolved DELFIA fluorometer (Wallac Victor
3,P e r k i n s -
Elmer, Shelton, Connecticut, USA). Percentage of specific
cell lysis was calculated as follows: (experimental release -
spontaneous release)/(maximum release - spontaneous
release) × 100. Maximum release was determined from 5
×1 0
3 labeled target cells lysed with DELFIA lysis buffer
(Perkin-Elmer) in triplicate wells. Spontaneous release was
measured by incubating 5 × 10
3 target cells in the absence
of effector cells in triplicate wells. Results are reported as
mean values of triplicate wells.
In vivo depletion of immune cell subsets
In vivo Ab ablation of rat anti-CD4 (GK1.5), anti-CD8
(53-6.7), and anti- NK1.1 (PK136) monoclonal antibo-
dies (100 μg/injection/mice) (all from BioLegend, San
Diego, CA) were performed by intraperitoneal injection
to deplete CD4
+ T cells, CD8
+ T cells, and NK cells,
respectively, on day 1 before vaccination and on days 2,
5 and 8 after tumor challenge. Normal rat IgG (Sigma)
w a su s e da san e g a t i v ec o n t r o l .C 5 7 B L / 6m i c e( n =5 )
were immunized by intratumoral injection with DC-
based vaccine pulsed with CMQ-treated TCLs on days
7, 10 and 13 after tumor challenge. Survival of mice was
observed up to 40 days after tumor challenge.
Different delivery systems of DC-based vaccines pulsed
with CMQ-treated tumor cell lysates
C57BL/6 mice (n = 6) were immunized by intratumoral,
intranodal, or subcutaneous injection with DC-based
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and 13 after tumor challenge. One week after immuni-
zation, right flanks of mice were subcutaneously inocu-
lated with B16 tumor cells (10
5 cells/50 μl/mouse).
Tumor volumes were determined from the length (L)
and width (W) of test tumors, as measured with a cali-
per in a blinded manner by the formula: V = L × W
2/2.
Survival of mice was recorded over 44 days following
tumor challenge.
Analysis of DC phenotype
DCs were harvested and washed in staining buffer (ster-
ile PBS, 1% FBS) before addition of antibodies. Nonspe-
cific binding was blocked with anti-CD16/CD32 (BD
Pharmingen, San Diego, CA) for 15 minutes at 4°C.
Cells were then stained with anti-CD11c-phycoerythrin
(PE) (BD Pharmingen, San Diego, CA) and related phe-
notypic maturation markers of DCs [anti-CD40-fluores-
cein isothiocyanate (FITC), anti-CD80-FITC, anti-CD86-
FITC, and anti- I-A/I-E -FITC, all from BD, Pharmin-
gen]. Cells were incubated for 30 minutes at 4°C before
washing with staining buffer twice. Cells were then
resuspended and fixed in 200 mL 2% formaldehyde
solution before analysis with a FACS LSR2 flow cyt-
ometer using DIVA software (BD Biosciences, San
Diego, CA).
Mixed lymphocyte reaction induced by DCs
Responder CD4
+ T cells and CD8
+ Tc e l l s ,u s e df o rt h e
allogeneic T-cell reaction, were isolated by being passed
through mononuclear cells in a MACS column (Miltenyi
Biotec, Auburn, CA). DCs were treated for 24 hours
with CMQ (0.1, 0.5 and 1 μM) or colchince (2.5 μM).
After harvesting, DCs (5 × 10
3 cells) were added to 1 ×
10
5 allogeneic T cells in flat-bottomed 96-well microtiter
culture plates. During the last 16 of the 72 hours of cul-
turing, proliferation of T cells was determined using a
5-bromo-2-deoxyuridine (BrdU)-based Cell Proliferation
ELISA kit (Roche, Heidelberg, Germany) according to
the manufacturer’s instructions. The T-cell proliferation
was expressed as the stimulation index: the OD450 value
of co-culture of treated-DCs and T cells divided by the
v a l u eo fc o - c u l t u r eo fD M S O - t r e a t e d - D C sc o - c u l t u r e d
with T cells. Results are presented as means of the
values of triplicate cultures.
Statistical analysis
Data are presented as mean ± SEM or ± SD. Statistical
analyses were carried out with GraphPad Prism 5.0 (San
Diego, CA). Statistical difference between groups was
compared by Student’s t-test. Differences in survival
time and rate were evaluated by a log-rank (Mantel-
Cox) test of the Kaplan-Meier survival curves. All statis-
tical tests were two-sided. P values less than 0.05 were
considered statistically significant (*, P < 0.05; **, P <
0.01; ***, P < 0.001).
Results
Effect of various microtubule-depolymerizing agents on
growth of B16 melanoma cells
Several 2-phenyl-4-quinolone derivatives including
CMQ and FMQ have been shown to confer anti-tumor
activity via the mitochondria (intrinsic pathway), death
receptors (extrinsic pathway), or endoplasmic reticulum
(ER) stress [31,36,37]. To evaluate whether CMQ and
FMQ and colchicine (chemical structures shown in
Figure 1A) as microtubule-depolymerizing agents, can
cause cell death leading to immunogenic cell death, we
examined their effect along with the effect of doxorubi-
cin as positive control on cell proliferation of B16 mela-
noma cells. Twenty-four hours post treatment,
colchicine effectively inhibited approximately 50% of test
cell growth at concentrations greater than 0.05 μM.
CMQ and FMQ exerted similar inhibitory patterns in a
dose-dependent manner at concentrations from 0.1 to
2.5 μM, and inhibition reached a plateau at approxi-
mately 2.5 μM (Figure 1B). Doxorubicin inhibited tumor
cell growth at all the concentrations tested in this study.
Our findings suggest that CMQ and FMQ conferred a
similar cytotoxic effect on B16 tumor cells growth to
doxorubicin. Colchicine apparently exerts different cyto-
toxic patterns on growth of B16 melanoma cells.
Effect of specific microtubule-depolymerizing agents on
expression of immunogenic cell death-related proteins
and tumor-associated antigens
Recent studies have revealed that increased expression
of DAMPs, a characteristic of immunogenic cell death,
can increase immunogenicity in cancer vaccines via ER
stress or other signaling pathways [38-40]. Whether
microtubule-depolymerizing agents can induce DAMPs
has not, to our knowledge, been previously reported.
Therefore, we measured the expression of several
DAMPs (HSP70, HSP90, CRT and HMGB1) in TCLs
from B16 cells after treatment with 2.5 μM colchicine,
CMQ, FMQ or doxorubicin. The MDAs colchicine,
C M Qa n dF M Qi n d u c e dt h ee x p r e s s i o no fH S P 7 0 ,
HSP90 and HMGB1 in tumor cells as compared with
cells treated with vehicle control, but did not affect the
expression of CRT (Figure 1C). Doxorubicin induced
higher levels of expression of the same DAMPs than the
MDAs tested. Specific tumor-associated antigens includ-
ing glypican-3 and survivin are markers for melanoma
and many cancer cell types [41]. The level of glypican-3
and survivin in cell lysate was elevated after test tumor
cells were treated with colchicine, CMQ, FMQ or dox-
orubicin (Figure 1D). These results suggest that the
three MDAs increase the expression of DAMPs and the
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Page 5 of 15Figure 1 Expression of damage-associated molecular patterns (DAMPs) and tumor-associated antigens in tumor cell lysates of treated
B16 melanoma. (A) The chemical structures of microtubule-depolymerizing agents and doxorubicin tested in this study are shown in A. (B)
Effect of MDAs and doxorubicin on cell viability of B16 melanoma cells. Mouse B16 melanoma cells were treated with the indicated
concentrations of colchicine, doxorubicin (DX), 2-(3-chlorophenyl)-6,7-methylenedioxyquinolin-4-one (CMQ) and 2-(3-fluorophenyl)-6,7-
methylenedioxyquinolin-4-one (FMQ) for 24 h, as shown in B. The values are represented as the percentage of viable cells; the vehicle control
group was regarded as 100% viable. Cell viability was determined by MTT assay and data were expressed as mean ± S.D. for triplicate culture
samples. (C&D) Effect of MDAs and doxorubicin on expression of damage-associated molecular patterns (DAMPs) and tumor-associated antigens
in treated B16 melanoma cells. B16 tumor cells were treated for 24 h with vehicle control, colchicine (C), CMQ, FMQ or DX, at a concentration of
2.5 μM. After treatment, TCLs were obtained through four freeze-thaw cycles. Western blot analysis for protein expression of damage-associated
molecular patterns (DAMPs), heat shock protein 70 (HSP70), heat shock protein 90 (HSP90), calreticulin (CRT) and high-mobility group box-1
(HMGB1), is shown in C, and expression of tumor-associated antigens including glypican-3 and survivin, is shown in D. Expression of b-actin was
used as an internal control. The results show one representative experiment of three independently performed experiments.
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and glypican-3, but the patterns of these effects may dif-
fer among the MDAs and doxorubicin.
Microtubule-depolymerizing agents can enhance the
efficacy of therapeutic immunity provided by tumor cell
lysate-pulsed dendritic cell vaccines
The results described above suggest that MDA-condi-
tioned TCLs may induce an immunogenic response in
vivo and thus augment the efficacy of specific dendritic
cell-based vaccines. A mouse model challenged subcuta-
neously with B16 cells and immunized with test DC vac-
cines intratumorally was used to explore this possibility
(Figure 2A). Mice receiving PBS only, unpulsed mature
DCs, or TCL-DMSO-pulsed DCs showed no significant
cytotoxic T lymphocyte (CTL) activity against B16 mela-
noma (Figure 2B). However, mice vaccinated with TCL-
C-pulsed DCs (P = 0.013 versus TCL-DMSO group)
and TCL-CMQ (tumor cell lysate treated with CMQ)
-pulsed DCs (P = 0.015 versus TCL-DMSO group were
found to have significantly enhanced CTL activity with
the ratio of effector cells to target cells (E:T) increased
from 20:1 to 80:1. These CTL activities were comparable
with those of the positive control, TCL-DX-pulsed DC
vaccine (P = 0.018 versus TCL-DMSO group).
With respect to tumor growth, time-course experi-
m e n t sr e v e a l e dt h a tt u m o rg r o w t hw a ss i g n i f i c a n t l y
inhibited in the TCL-DMSO (P = 0.02 versus vehicle
group) in comparison with the unpulsed DC (P =0 . 0 2
versus vehicle group) and vehicle group on day 24 post
tumor inoculation (Figure 2C). However, treatment with
TCL-C (P = 0.011 versus TCL-DMSO group) and TCL-K
(P = 0.020 versus TCL-DMSO group) showed significant
tumor suppression, which was comparable to that of the
positive control, TCL-DX (P = 0.012 versus TCL-DMSO
group). Furthermore, the survival time and survival rate
of test mice in the TCL-C, TCL-CMQ and TCL-DX vac-
cinated groups (all with P < 0.001) were significantly
improved in comparison with those of the TCL-DMSO
group (Figure 2D). This trend was in accordance with
that for the suppression of tumor growth (Figure 2C).
Results for mice vaccinated with TCL-FMQ-pulsed DCs
were similar to those vaccinated with TCL-CMQ pulsed
DCs (data not shown). These results suggest that the effi-
cacy of DC-based vaccines pulsed with TCLs can be
effectively elevated by treating test tumor cells with the
MDAs, colchicine, CMQ and FMQ.
Specific immune cell subsets involved in vaccine efficacy
In order to investigate which immune cell subsets play
roles in therapeutic immunity of test DC vaccines, mice
were injected intraperitoneally with either anti-CD4,
-CD8, or -NK1.1 monoclonal antibodies (mAb) to
deplete the respective cell types. The vaccinated mice
treated with rat-IgG (P = 0.028, versus control group) or
anti-CD4 mAb (P = 0.049, versus control group) showed
significantly increased survival rates and survival times
as compared with the control group (Figure 3). How-
ever, the survival rate of the vaccinated mice injected
with anti-CD4 mAb was 40% lower than the rat-IgG
group. On the other hand, vaccinated mice treated with
anti-CD8 or anti-NK1.1 mAb did not exhibit a statistical
change in survival rate and survival time as compared
with control group (P > 0.05, versus control group).
Depletion of CD8
+ T cells and NK cells thus virtually
completely blocked the protective activity of DC vac-
cines pulsed with CMQ-treated TCLs. These results
indicate that tumor-specific CD8
+ T cells and NK cells
play a crucial role in the observed therapeutic immunity
induced by DC vaccines pulsed with CMQ-treated TCLs
against B16 melanoma, whereas CD4
+ Tc e l l sa r eo n l y
partially involved in the antitumor activity.
Effect of DC culture conditions on vaccines
Since IL-12p70 plays a critical role in the effective prim-
ing of a TH1 anti-tumor immune response and CTL
activities [26,42], and IL-10 has been shown to inhibit the
production of IL-12p70 in murine DCs [43,44], we next
evaluated the expression and balance of IL-12p70 and IL-
10 activities in various TCL-pulsed DC vaccines. To
address the possible effect of CMQ on test DCs, we
determined the release of IL-12p70 and IL-10 expressed
by murine DCs pulsed with or without CMQ-treated
TCLs. Experiments were carried out simultaneously by
co-treatment or co-incubation for 12 hours and stimula-
tion with or without LPS in the absence of GM-CSF and
IL-4 (Figure 4A). A higher production of IL-12p70 and a
lower production of IL-10 were detected in DCs with
LPS stimulation only (maDCs) than pulsed DCs co-cul-
tured with TCL-CMQ and LPS (CTCL-CMQ) or with
TCL-CMQ first and stimulated with LPS later (TCL-
CMQ) (Figure 4A). DCs treated with TCL-CMQ showed
increased production of IL-12p70 compared with imDCs
and the CTCL-CMQ group, similar to the maDCs group,
whereas the production of IL-10 was significantly
increased in this group in comparison with other groups.
The maDCs were more effective than TCL-CMQ and
CTCL-CMQ in increasing production of IL-12, whereas
TCL-CMQ was more effective than CTCL-CMQ and
maDCs in increasing production of IL-10. Overall, these
results suggest that it may bep o s s i b l et oi m p r o v eI L - 1 2
production and decrease IL-10 production to enhance
anti-tumor activity of TCL-CMQ.
Treatment with IL-4 accompanied by GM-CSF can
promote IL-12p70 expression and inhibit IL-10 expres-
sion in murine or human DCs [45-47]. We, therefore,
hypothesized that adding GM-CSF and IL-4 to test cul-
ture during the pulsing and stimulation period may
Wen et al. Journal of Biomedical Science 2011, 18:44
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Page 7 of 15Figure 2 Therapeutic immunity of DC vaccines pulsed with various tumor cell lysates, against B16 melanoma. (A) Schematic
representation for vaccination. C57BL/6 mice were challenged subcutaneously with 1 × 10
5 B16 cells and vaccinated with different preparations of
TCL-pulsed DCs when the tumor volume reached to 50-80 mm
3. On day 10 after the secondary boosting, splenocytes were harvested for cytotoxic
T lymphocyte activity (CTL) assay. (B) CTL activities in test mice. Splenocytes from vaccinated or control group mice (n = 8 mice per group) were
collected and CTL activity assayed with target tumor cells. Test DCs were pulsed with TCL-DMSO, TLC-DX, TLC-C, or TCL-CMQ. PBS-treated mice
(Ctrl) did not receive DC vaccine, only a PBS injection. Test mice in the mature DC group (maDC) were subjected to vaccination with unpulsed
mature DCs. (C) Tumor growth of treated mice. Tumor size of each group (n = 8 mice per group) was measured on indicated days. (D) Survival
rates of treated mice. Survival of mice (n = 12 mice per group) was observed after tumor challenge. For all experiments, the TCL-FMQ groups
showed a similar pattern of activities as that of TCL-CMQ and hence the data are not shown. All data are expressed as mean ± S.E.M.
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10. We therefore cultured DCs without either GM-CSF
or IL-4, with GM-CSF only, or with GM-CSF and IL-4
to measure the production of IL-12p70 and IL-10 in test
cells treated as mentioned above and shown in Figure
4A-C. Supplement of GM-CSF and IL-4 conferred the
highest level of expression of IL-12p70 and lowest level
of expression of IL-10 (Figure 4C) as compared with the
other culture conditions (Figure 4A and 4B). The
increase in IL-12p70 and decrease in IL-10 expression
levels suggested that TCL-CMQ and CTCL-CMQ treat-
ments could be greatly improved by supplement with
GM-CSF only or by addition of both GM-CSF and IL-4
concomitantly. TCL-CMQ conferred the highest levels
of IL-12p70 production and lowest levels of IL-10 in
comparison with other test groups. These results suggest
that TCL-CMQ treatment combined with culturing in
GM-CSF and IL-4 may augment the efficacy of DC-
based vaccines pulsed with TCLs.
Effect of different administration routes on therapeutic
immunity of DC-based vaccines pulsed with tumor cell
lysates
IL-12p70 has been shown to be beneficial when used as
an adjuvant with DC-based vaccines, either via systemic
or local delivery, especially when administered via intra-
tumoral injection [43,44,48]. It is clinically important to
establish optimal methods of administration for effective
delivery of TCL-pulsed DC-based vaccines. To evaluate
of efficiency of vaccine delivery, test vaccines were
injected intratumorally, intranodally, intravenously and
subcutaneously into the left flanks of mice. Mice receiv-
ing intratumoral injection of TCL-CMQ DC vaccines (P
< 0.01, versus control group) showed a stronger thera-
peutic immunity than all the other delivering systems
tested (all P < 0.05, versus control group) with respect
to tumor suppression (Figure 5A). Animal survival rate
and time, as analyzed by log-rank (Mantel-Cox) test
(Figure 5B), were also drastically increased by vaccina-
tion via intratumoral injection (P = 0.0011, versus con-
trol group) as compared to vaccination via intranodal
injection (P = 0.0319 versus control group), intravenous
injection (P = 0.0318, versus control group) or subcuta-
neous injection (P = 0.0355 versus control group).
Nonetheless, it is important to note that the intranodal,
intravenous and subcutaneous modes of vaccine delivery
also had a significant effect on survival rate and time of
test mice in comparison with non-vaccinated (control)
mice. These results suggest that the DC-based vaccine
pulsed with TCLs delivered by intratumoral injection
may be an efficient experimental mode for laboratory
animal and perhaps human clinical studies.
Microtubule-depolymerizing agents enhance maturation
of dendritic cells and CD4
+ T and CD8
+ T cell proliferation
Previous studies reported that some microtubule-target-
ing agents including colchicine [15,16], vincristine [17]
and paclitaxel [49,50] induced maturation of DCs and
further augmented CD4
+ Ta n dC D 8
+ T cell activities
or antigen cross-presentation activity. However,
although 2-phenyl-4-quinolone derivatives have pre-
viously been shown to confer strong anti-tumor activity
[32,36,51], whether these CMQ and FMQ phytocom-
pound-derived chemicals could induce maturation of
DCs and subsequently enhance CD4
+ Ta n dC D 8
+ T
cell activities has not been reported. As a follow up, we
treated DCs with various concentrations of CMQ (0.1,
0.5 and 1 μM), colchicine (2.5 μM) and LPS (1 μg/ml).
As shown in Figure 6A, expression of DC maturation
surface markers such as CD40, CD80, CD86 and MHC-
II were greatly increased after treatment with CMQ as
compared with those of control group cells. Levels of
induction of DC maturation surface markers after treat-
ment with CMQ were comparable to those observed for
colchicine, but were less than those observed after LPS
treatment. Co-cultivation of CD4
+ To rC D 8
+ Tw i t h
DCs showed that CMQ could significantly augment
CD4
+ Ta n dC D 8
+ T cell proliferation (Figure 6B).
Treatment with FMQ showed similar effects (data not
shown). Our findings thus suggest that CMQ and FMQ
can induce maturation of DCs and in turn enhance CD4
+ T and CD8
+ T cell proliferation.
Figure 3 Determination of immune cell subsets responsible for
protective immunity induced by test DC vaccines. Preparations
of anti-CD4 (GK1.5), anti-CD8 (53-6.7), and anti-NK1.1 (PK136)
antibodies were administered by intraperitoneal injection on day 1
in test mice prior to vaccination on days 2, 5 and 8 after tumor
challenge as described in Materials and Methods. C57BL/6 mice (n
= 5) were immunized intratumorally with test DC vaccines on
days 7, 10 and 13 after tumor challenge as described in Materials
and Methods and inoculated with B16 melanoma cells (10
5 cells/
50 μl/mouse) on day 0. Statistical difference was calculated by
log-rank (Mantel-Cox) test for mouse survival and P values of less
than 0.05 were considered significant as compared with control
group (*, P < 0.05).
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Page 9 of 15Figure 4 Effect of GM-CSF and IL-4 on IL-12p70 expression in DCs treated with tumor cell lysates. (A-C) IL-12p70 and IL-10 expression in
DCs pulsed with CMQ-treated TCLs under different culture conditions. After harvesting, DCs were incubated in three kinds of culture conditions
with or without GM-CSF (20 ng/ml) plus IL-4 (20 ng/ml), and were treated as follows: vehicle (imDC), LPS (maDC), TCL plus LPS for 24 h (CTCL-
CMQ) or TCL for 12 h and then LPS for 24 h (TCL-CMQ) as described in Materials and Methods. The level of IL-12p70 released into supernatants
of test DC cultures was assayed by ELISA. Statistical difference among test groups was analyzed by Student’s t-test. P values less than 0.05 were
considered statistically significant (*, P < 0.05; **, P < 0.01; ***, P < 0.001 versus the maDC group).
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The first therapeutic cancer vaccine, Sipuleucel-T (Pro-
venge
®), which uses antigen-presenting cell (APC) tech-
nology involving dendritic cells (DCs) for cancer
immunotherapy was approved by the FDA in 2010 [52].
This success highlights the potential of ex vivo treated
DCs as therapeutic vectors for various kinds of cell-
based cancer vaccines. Immunization of cancer patients
using their own DCs that have been loaded with tumor
associated antigens (TSAs) and/or immune-modifiers ex
vivo is becoming an increasingly popular strategy in the
development of cancer vaccines [6,53]. Microtubule-
depolymerizing agents (MDAs) such as colchicine and
vincristine, which are used clinically in cancer che-
motherapy, have recently been shown to enhance
specific immune functions of DCs [15-17]. Whether or
n o tM D A ss u c ha st h e s ec a nb ee m p l o y e df o ru s ei n
DC-based cancer vaccines has, to the best of our knowl-
edge, not previously been reported. To address this pos-
sibility, our current study explored the effect three
MDAs - the well-known drug, colchicine, and two 2-
phenyl-4-qunilone derivatives (CMQ and FMQ) - on
immunogenic tumor cell death when used as “adjuvants”
of TCL-pulsed DC vaccines in a therapeutic mouse
model. MDAs were able to effectively induce the expres-
sion of immunogenic cell death-related proteins in tar-
geted tumor cells, and augment the efficacy of TCL-
pulsed DC-based vaccines.
Previous studies have shown that colchicine can elicit
CD4
+ and CD8
+ T cell responses, induce antibody
response, and promote antigen cross-presentation by
murine dendritic cells [15,16,54,55]. In this study, we
show that colchicine also induces the expression of
DAMPs and tumor-associated antigens (TAAs) in dying
B16 melanoma cells (Figure 1C-D). In addition, DC-
based vaccines pulsed with colchicine-treated TCLs
were able to enhance therapeutic immunity (Figure 2B-
D). We also tested two 2-phenyl-4-quinolone deriva-
tives, in parallel with colchicine, and doxorubicin (as a
positive control), for their effect on this cancer vaccine
approach. CMQ and FMQ showed effects comparable
to colchicine; however, the detailed mechanism(s) of
action of these MDAs remain unclear. Optimization of
dosage and improvement in formulation of this MDA-
TCL combination will be important for future use in
DC-vaccines.
It has been put forward that DCs pulsed with TAA pre-
parations derived from freeze-thaw cycle treatment of
autologous TCLs are a promising approach to cancer
immunotherapy as a wide repertoire of different TAAs
are present in the lysate [25,26,28,56]. Based on knowl-
edge of antigen-processing and cell trafficking of DC
activities in vivo, it is generally believed to be important
to optimize the in vitro/ex vitro culture conditions to
generate efficacious vaccines for cancer immunotherapy.
In cytokine-regulated anti-tumor immunity, IL-12p70 is
recognized as a key cytokine in the promotion TH1
immune response [44]. IL-10 inhibits the releases of IL-
12p70, and is often considered as unfavorable for pro-
moting anti-tumor immunity. We showed here (Figure
4 A - C )t h a ts u p p l e m e n to fG M - C S Fo n l yo rG M - C S F
plus IL-4 into the culture medium of a DC-based vaccine
can drastically alter the balance of IL-12p70 versus IL-10
levels in TCL-pulsed, LPS-activated DCs. Hatfield et al.
reported that DCs pretreated with TCLs and then acti-
vated by LPS treatment expressed a substantially reduced
level of IL-12p70 and a substantially increased level of
IL-10 [26]. Interestingly, here we show that supplement
of the cytokines GM-CSF and IL-4 to the culture
Figure 5 Effect of different administrative routes on DC-based
vaccines pulsed with specific tumor cell lysates. C57BL/6 mice
(n = 6) were immunized by intratumoral (I.T.), intranodal, (I.N.) or
subcutaneous (S.C.) injection with DC-based vaccines pulsed with
CMQ-treated TCLs on days 7, 10 and 13 after tumor challenge. One
week post vaccination, right flanks of mice were subcutaneously
inoculated with B16 melanoma cells (10
5 cells/50 μl/mouse). During
the following 45 days post tumor challenge, tumor volume (A) and
survival time (B) of mice was observed and measured as described
in Materials and Methods. Analysis of statistical differences among
test groups is described in Materials and Methods. P values of less
than 0.05 were considered statistically significant (*, P < 0.05; **, P <
0.01; ***, P < 0.001).
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Page 11 of 15medium throughout the entire TCL-pulse/LPS-activation
incubation period can drastically reverse such IL-12p70/
IL-10 expression ratio (Figure 4A-C). We therefore
believe that this protocol could increase the potency of
DC vaccines for use in anti-tumor vaccination [26].
Studies on DC-vaccines against cancers have used a
number of different modes of administration for deliv-
ery. Unfortunately, little or no comparative analysis of
those delivery systems is available. For future potential
clinical application, we consider that it is important to
Figure 6 Effect of treatment with different microtubule-depolymerizing agents on expression of cell-surface markers and CD4
+ and
CD8
+ T-cell proliferation in mouse bone marrow-derived immature dendritic cells. (A) Expression of surface markers on DCs. Cells were
treated for 24 h with CMQ (0.1, 0.5 and 1 μM), colchicine (2.5 μM) and LPS (1 μg/ml), and harvested. Examination for the expression of CD40, CD80,
CD86, MHC class II and CD11c markers was performed by flow-cytometry. The levels of CD40, CD80, CD86, MHC class II were expressed as mean
fluorescence intensity (MFI). (B) CD4
+ and CD8
+ T-cell proliferation. After indicated treatments, treated DCs were co-cultured with CD4
+ T cells or CD8
+
T cells in a ratio of 1:20 (DCs versus CD4
+ T cells or CD8
+ T cells) for 72 h. T-cell proliferation was determined in vitro using a BrdU proliferation ELISA
kit (Roche, Heidelberg, Germany) according to the manufacturer’s instructions. The T-cell proliferation was expressed as the stimulation index, the
OD450 value of co-culture of treated-DCs and T cells was divided by the value of co-culture of DMSO-treated-DCs co-cultured with T cells. All Data
were expressed as mean ± S.D. P values less than 0.05 were considered statistically significant (*, P < 0.05; **, P < 0.01; ***, P <0 . 0 0 1 ) .
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desirable for such vaccines. Intratumoral injection of
test vaccines elicited the best therapeutic effects among
all tested administrative routes (Figure 5A and 5B) in
this study. In cancer patients, DCs often present in an
immature or dysfunctional state, especially tumor-infil-
trating DCs, thereby preventing stimulation of tumor-
specific T cells [57]. Our findings suggest that, for large
size tumors, intratumoral injection of DC vaccines, may
be the most efficacious delivery mode. However, intratu-
moral injection has several disadvantages including lack
of promotion of systemic circulation, and inconvenience
of delivery into tumor sites in some clinical tumors.
Therefore combinations of different administration
modes still need to be considered to achieve efficacy.
Previously we developed particle bombardment/gene
gun technology, by which 0.1 to 1 million 1-3 μMg o l d
particles (biologically inert) can penetrate into epidermal
or dermal tissues [58]. We also reported that such bal-
listic bombardment can systematically generate evenly
distributed, microscopic tissue tracks, creating mild,
defined tissue and microvascular wounding in target
skin areas [59,60]. We propose that anti-cancer vaccines
may be optimized by making use of the particle bom-
bardment technology as a systematic, highly effective
and multiple site-delivery mode for the pretreatment of
tumor-bearing mice areas (especially for the high num-
ber, metastasized, microscopic melanoma nodules),
before administration of DC-based vaccines. In future
possible applications, melanoma patients may be admi-
nistered TCL-DC anti-cancer vaccines using a combina-
tion of gene gun and intratumoral injection of TCL-DCs
Apoptotic cell death was previously recognized mainly
as being tolerogenic, whereas necrosis was considered
immunogenic. Recently, it was found that apoptotic cell
death also can induce immunogenic cell death via
expression of DAMPs [9,10,23,39,61]. A number of stu-
dies have also shown that DCs pulsed with apoptotic
tumor cells can induce immunity against tumors
[23,61]. Whether human DCs pulsed with MDA-treated
tumor cells could elicit a strong immunity against
human cancers needs to be investigated in future clini-
cal studies.
Regardless of which pathways are targeted by DC-based
vaccines to treat tumor cells, apoptotic or necrotic, it is
generally agreed that treatment needs to result in immu-
nogenic cell death, especially in expression of DMAPs
[8,38-40]. Currently, physical methods includingg-irradia-
tion [62], heat stress [26] and UV [63] are used to
enhance expression of DMAPs to generate strong tumor-
specific immunity. And chemotherapeutic agents includ-
ing doxorubicin, mitoxanthrone, oxaliplatin have been
shown to confer these activities [7,64,65]. Here, we show
that MDAs can also induce immunogenic cell death and
confer immunity against test tumors. We speculate that a
combination of physical and chemical methods may help
upgrade efficacy of either the TCL- or apoptotic tumor
cell-pulsed DC vaccines. Future research is required to
address these possibilities.
Recent studies have suggested that microtubules play a
role in antigen-presenting presentation of dendritic cells
[13,54]. An increasing body of evidence has also shown
that microtubule-targeted agents including vincristine,
colchicine and palitaxel can promote DC-mediated
immune responses or enhance efficacy of combined che-
motherapy [15-17,49,66]. The binding site of 2-pheny-4-
quinolone derivatives on microtubule proteins was
reported to be likely the same as the binding site of col-
chicine [32]. Our current findings revealed that 2-phe-
nyl-4-quniolone derivatives can enhance the maturation
of DC and mediate promotion of CD4
+ and CD8
+ T cell
proliferation (Figure 6A and 6B). The specific microtu-
bule-depolymerizing agents we studied here may thus
have potential for use as adjuvants for DC-mediated
vaccines for infectious diseases or melanoma cancers.
Conclusions
Three specific microtubule-depolymerizing agents - col-
chicine, 2-(3-chlorophenyl)-6,7-methylenedioxyquinolin-
4-one (CMQ) and 2-(3-fluorophenyl)-6,7-methylene-
dioxyquinolin-4-one (FMQ) - were found to effectively
induce expression of DAMPs proteins and augment the
therapeutic efficacy of DC-based vaccines pulsed with
TCLs. In test B16 melanoma mouse systems, CD8
+ T
cells and NK cells were found to be involved in the
observed therapeutic immunity. Further, supplementing
culture media with GM-CSF and IL-4 culture prior to
and during pulsing of MDA-treated DCs may enhance
the efficacy of vaccines. CMQ and FMQ were also able
to induce maturation of DCs and increase CD4
+ Ta n d
CD8
+ T cell proliferation. Our findings showed conclu-
sively that colchicines, CMQ and FMQ offer bifunc-
tional anti-tumor protection in a B16 melanoma model
in rodents: First, these chemicals upregulate tumor
DAMP, and cause immunogenic cell death of tumors;
second these MDAs strongly augment tumor antigen
presenting function of mature DC, which in turn
orchestrate CD4- and CD8-mediated tumor destruction.
The synergy of immunogenic cell death at level of
tumor cells, coupled with their subsequent adjuvant
effect for tumor antigen presentation at level of DC
lends significant import for cancer vaccine development.
Thus our findings strongly suggest that specific
microtubule-depolymerizing agents, especially
colchicine, may be suitable for clinical applications as
adjuvants in TCL-pulsed DC vaccines. In the future,
clinical studies on patients with advanced melanoma
should be considered.
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